Dr. Emily Drabant Conley is Chief Executive Officer of Federation Bio, a clinical stage biotechnology company pioneering a new modality of microbial cell therapies. Federation Bio’s high diversity microbial consortia are therapeutically optimized for efficacy and are manufactured from purified cell lines. Therapeutics from Federation Bio’s first-in-class consortia platform target multiple mechanisms of action and stably engraft in patients for durable benefit. The company’s pipeline includes a range of diseases from metabolic disorders to IBD to cancer.

Previously, Dr. Conley spent over a decade at 23andMe, where she helped scale the company from 30 employees into the world’s leading platform for genetic-driven drug discovery. As Vice President of Business Development at 23andMe, she architected visionary partnerships across pharma and biotech. Dr. Conley currently serves on the boards of Federation Bio, Nuvalent (NASDAQ: NUVL), and TMRW Life Sciences, and formerly served on the boards of Medrio, Lesbians Who Tech, and the UCSF Alliance Health Project.

Dr. Conley has received numerous awards and honors, including Endpoints News’ 20 Biopharma Leaders Under 40, Business Insider’s 30 Leaders Under 40, and Google Ventures’ 25 Women Shaping the Future of Technology.

Prior to industry, Dr. Conley was a research fellow at the National Institutes of Health and is co-author on more than 35 academic publications. She received her Ph.D. in Neuroscience from Stanford University School of Medicine, where she held fellowships from the National Science Foundation and Department of Defense. She graduated summa cum laude from Vanderbilt University with a B.A.